Home › Myriad Genetics to Seek BRCA CDx Approval From Japanese Regulators

Myriad Genetics to Seek BRCA CDx Approval From Japanese Regulators

Nov 07, 2016

NEW YORK (GenomeWeb) – Myriad Genetics said today that it will submit its BRACAnalysis CDx to Japan's Pharmaceuticals and Medical Devices Agency for regulatory approval, alongside AstraZeneca's PARP inhibitor Lynparza (olaparib).

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jan
30
Featured Webinar

A Long-Read vs. Short-Read Platform Comparison: Best NGS Approaches for Microbiome Studies

Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Feb
21
Featured Webinar

Case Study: 'Companion Informatics' to Automate Immunotherapy Manufacturing and Treatment

Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

What's Popular?

In Molecular Diagnostics

  1. Medicare Covers Adaptive Biotechnologies' ClonoSeq Assay

  2. Minimal Residual Disease Sequencing Poised to Grow Following Lag in Adoption

    Premium

  3. BioFluidica Applying Liquid Biopsy to Detect Leukemia While Reducing Biopsies

    Premium

  4. Qiagen EGFR Assay Approved in Japan as CDx to Pfizer NSCLC Drug

  5. Liquid Biopsy Panel Expansion Enables Admera Health to Add Immunotherapy Prediction

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.